SINGAPORE, June 24 – Scientists at A*STAR’s Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukemia cells that are detected by a unique group of immune cells.
By recognizing the lipids, the immune cells stimulate an immune response to destroy the leukemia cells and suppress their growth.The newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukemia immunotherapy, a statement said.
Leukemia is characterized by the accumulation of cancer cells originating from blood cells, in the blood or bone marrow.Current treatments for leukemia largely involve chemotherapy to eradicate all cancer cells, followed by stem cell transplants to restore healthy blood cells in the patients.
In a recent study reported in the Journal of Experimental Medicine (JEM) online, the team co-led by Dr Lucia Mori and Prof Gennaro De Libero identified a new class of lipids, methyl-lysophosphatidic acids (mLPA), which accumulate in leukaemia cells.
Following which, the team identified a specific group of immune cells, described as mLPA-specific T-cells that are capable of recognizing the mLPA in the leukaemia cells.
The detection triggers an immune response that activates the T cells to kill the leukaemia cells and limits cancer progression.
The efficacy of the T cells in killing leukaemia cells was also demonstrated in a mouse model of human leukaemia.
Thus far, only proteins in cancer cells have been known to activate T cells. This study is a pioneer in its discovery of mLPA, and the specific T cells which can identify lipids expressed by cancer cells.
Commenting on the discovery Principal Investigator at SIgN Dr Mori said that the identification of mLPA and its role in activating specific T cells was novel.
“This knowledge not only sheds light on future leukaemia studies, but also complements ongoing leukaemia immunotherapy studies focusing on proteins in cancer cells.
“Current treatments run the risk of failure due to re-growth of residual leukaemia cells that survive after stem cell transplants. T-cell immunotherapy may serve as a complementary treatment for more effective and safer therapeutic approach towards leukaemia,” she said in the statment.
Professor Laurent Renia, Acting Executive Director of SIgN said that this mode of immune recognition ofleukaemia cells was an insightful discovery that will create new opportunities for immunotherapy to improve the lives of leukaemia patients.
– BERNAMA
